Dry Eye Dx and Tx: Malfunctioning Mucins - Summary - MDSpire

Dry Eye Dx and Tx: Malfunctioning Mucins

Exploring the underappreciated role of mucins in dry eye disease reveals promising therapeutic avenues for improved management.

  • By

  • Roxanna Potter, OD

  • January 1, 2026

  • 4 min

Share

Objective:

To explore the critical role of mucins in dry eye disease and the potential for innovative therapeutic options targeting mucin dysfunction.

Key Findings:
  • Mucins are critical for maintaining tear film integrity and ocular surface health, and their dysfunction can exacerbate dry eye disease.
  • Damage to goblet cells can lead to altered mucus quality, contributing to dry eye disease and complicating treatment options.
  • There is a pressing need for better pharmaceutical options targeting mucin quality and quantity to improve patient outcomes.
Interpretation:

Understanding mucin dysfunction in dry eye disease may lead to innovative therapies that improve patient outcomes.

Limitations:
  • Current topical secretagogues are not available in the U.S., limiting treatment options for patients.
  • Oral secretagogues may have systemic side effects, which could deter their use in managing dry eye disease.
Conclusion:

As research on mucins progresses, new therapeutic strategies may emerge to enhance mucin function and alleviate dry eye symptoms, highlighting the need for urgent exploration in this area.

Original Source(s)

Dry Eye Dx and Tx: Malfunctioning Mucins

  • by Roxanna Potter, OD

  • January 1, 2026

Related Content

Adding Interventional DED Treatment to Your Practice

Interventional treatment for DED before refractive surgery biometry allows practices to offer options like advanced-technology intraocular lenses to more patients.

Supplying Ocular Nutritional Supplements

Consider these 5 tips for success.

Driving Progress in Dry Eye Care

WCO and Alcon renew global dry eEye education partnership

  • February 5, 2026

  • 3 min